Cyclacel Pharmaceuticals (NASDAQ:CYCC) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies that target cell cycle and cell proliferation mechanisms in oncology and hematology. The company’s research platform is built around small molecule inhibitors designed to selectively modulate key regulators of cell division, with the goal of improving treatment outcomes for patients with a variety of cancers and blood-related disorders.
The company’s lead asset, fadraciclib (formerly CYC065), is a potent cyclin-dependent kinase (CDK) 2/9 inhibitor that has advanced into clinical trials for solid tumors and hematologic malignancies. In addition, Cyclacel is developing a next-generation oral ATR inhibitor, CYC140, and other small molecule candidates aimed at exploiting vulnerabilities in tumor DNA damage response pathways. These programs are supported by preclinical research demonstrating synergy with existing therapies and potential for combination regimens.
Founded in 1996 in Dundee, Scotland, Cyclacel Pharmaceuticals has established operations in both the United Kingdom and the United States, with corporate headquarters in Berkeley Heights, New Jersey. Over its history, the company has forged strategic collaborations with academic institutions, contract research organizations and industry partners to expedite clinical development and broaden its scientific capabilities. Cyclacel’s global footprint includes clinical trial sites across North America and Europe, reflecting its commitment to serving diverse patient populations.
Under the leadership of Chief Executive Officer Patrick J. Mahaffy and Chief Scientific Officer Steven M. Russell, Cyclacel maintains a focus on advancing its pipeline through rigorous clinical evaluation and regulatory engagement. The company’s management team combines experience in drug discovery, clinical development and regulatory affairs to navigate the complexities of oncology drug approval. Looking ahead, Cyclacel aims to secure proof of concept for its key candidates and pursue partnerships to support late-stage development and commercialization efforts.
